Treating Scalp Psoriasisdoi:10.1177/247553030006a00302Robert CarruthersRobert CarruthersMount SinaiRobert CarruthersPsoriasis Forum
This video demonstrates techniques to treat scalp psoriasis, including how to apply treatments to the scalp and how to remove hard scale. Patient... 其它视频 4:09 Approach to Tinea 0 人观看 1:25 Dermatology & Skin Diseases : The Causes of Acne Vulgaris 3 人观看 11:08 What is ...
The symptoms appear to be essentially localized to the face, to the neck and to the scalp, but can also appear all over the body. [0016] Thus, the applicant has discovered that one of the essential characteristics of sensitive skin is linked to the liberation of nitrogen monoxide and ...
Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for...
Patients with psoriasis have itchy and scaly patches of skin on the body, commonly affecting the scalp, elbows, chest and/or knees. Up to 80% of people with psoriasis also have scalp psoriasis, and this can be difficult to treat.British Journal of Dermatology...
Compositions useful for the treatment of hyperproliferative dermal diseases of the scalp. Specifically, topical gel and liquid compositions that include calcipotriol and nicotinamide in a polyethylene glycol-based carrier, for topical application to the scalp.EVEN-CHEN, ZEEV...
Compositions useful for the treatment of hyperproliferative dermal diseases of the scalp. Specifically, topical gel and liquid compositions that include calcipotriol and nicotinamide in a polyethylene glycol-based carrier, for topical application to the scalp.ZEEV EVEN-CHEN...
The present invention relates to a therapeutic agent for nail and scalp psoriasis comprising an IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as monoclonal antibodies that bind IL-17RA, and method of using the same.Nirula Ajay...
The present invention relates to a therapeutic agent for nail and scalp psoriasis comprising an IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as monoclonal antibodies that bind IL-17RA, and method of using the same.Ajay Nirula...
Response rates/mean percentage improvements at W48 (VOYAGE-1) were numerically greater with guselkumab than adalimumab (e.g., NAPSI improvement: 75.6% vs. 60.9%). Conclusions: Guselkumab-treated patients with psoriasis and self-reported PsA showed meaningful improvements in...